<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04588311</url>
  </required_header>
  <id_info>
    <org_study_id>ANZIC-RC/CF001</org_study_id>
    <secondary_id>U1111-1242-3694</secondary_id>
    <secondary_id>2020-003388-24</secondary_id>
    <nct_id>NCT04588311</nct_id>
  </id_info>
  <brief_title>ErythroPOietin Alfa to Prevent Mortality and Reduce Severe Disability in Critically Ill TRAUMA Patients</brief_title>
  <acronym>EPO-TRAUMA</acronym>
  <official_title>A Randomised, Double-blind, Placebo-controlled Trial of Erythropoietin Alfa Versus Placebo in Mechanically Ventilated Critically Ill Patients Following Traumatic Injury</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Australian and New Zealand Intensive Care Research Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University College Dublin</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical Research Institute of New Zealand</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical Research Future Fund (MRFF)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Health Research Board, Ireland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Health Research Council, New Zealand</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Irish Critical Care Clinical Trials Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>ANZICS Clinical Trials Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Monash University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Australian and New Zealand Intensive Care Research Centre</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The EPO-TRAUMA study is a prospective, multi-centre, double-blind, phase III, randomised&#xD;
      controlled trial evaluating the efficacy of epoetin alfa compared to placebo in reducing&#xD;
      mortality and severe disability at six months in critically ill trauma patients.&#xD;
&#xD;
      2500 mechanically ventilated ICU patients admitted with a primary trauma diagnosis presenting&#xD;
      to the ICU will be recruited into the study from participating study centres in Australia,&#xD;
      New Zealand, Europe, and Saudi Arabia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Trauma can cause many injuries, some of which are life-threatening and require treatment in&#xD;
      an intensive care unit (ICU). Despite best available treatment and therapies, people who&#xD;
      sustain a critical traumatic injury are at greater risk of death or long-term disability.&#xD;
      From 2010 to 2015, approximately 9% of people admitted to an ICU in Australia and New Zealand&#xD;
      for treatment of their injuries, did not survive. In Victoria, 6-months post injury,&#xD;
      approximately 31% of people who were critically injured developed severe disabilities or&#xD;
      died.&#xD;
&#xD;
      Following a traumatic injury, a number of complex pathways are activated by the body. These&#xD;
      pathways can occur over hours or weeks and may lead to damage of cells, tissues or blood&#xD;
      vessels and may destroy other healthy tissue. The treatment of traumatic injury focuses on&#xD;
      trying to minimise further damage that can occur after the initial injury.&#xD;
&#xD;
      Erythropoietin is a glycoprotein hormone essential for erythropoiesis and was first purified&#xD;
      in 1977. Its human recombinant analogues known as erythropoiesis stimulating agents (ESAs)&#xD;
      are approved for human therapeutic use. However, erythropoietin is also a pleiotropic&#xD;
      cytokine with effects beyond just erythropoiesis. Studies in animals have demonstrated the&#xD;
      potential protective effects of erythropoietin to organs including the brain, kidney, liver&#xD;
      and heart, and anti-inflammatory properties.&#xD;
&#xD;
      Previous research suggests the use of the ESA called epoetin alfa, increases the number of&#xD;
      patients surviving severe trauma and reduces the risk of disability in those who survive.&#xD;
&#xD;
      The primary aim of the study is to determine the efficacy of epoetin alfa compared to placebo&#xD;
      in reducing mortality and severe disability at six months in critically ill trauma patients.&#xD;
&#xD;
      2500 mechanically ventilated ICU patients admitted with a primary trauma diagnosis presenting&#xD;
      to the ICU will be recruited into the study from participating study centres in Australia,&#xD;
      New Zealand, Europe, and Saudi Arabia.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 9, 2020</start_date>
  <completion_date type="Anticipated">March 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2025</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Combined proportion of participants who have died or have severe disability (WHODAS 2.0 &gt; 25)</measure>
    <time_frame>6-months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality at 6-months</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality at ICU discharge</measure>
    <time_frame>6-months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality at Hospital discharge</measure>
    <time_frame>6-months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality at day 28</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with a favourable Glasgow Outcome Score Extended (GOSE) (GOSE 5-8) compared to those have have died (GOSE 1), or have severe disability (GOSE 2-4).</measure>
    <time_frame>6-months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with composite thrombotic vascular events (deep vein thrombosis (DVT), pulmonary embolism (PE), myocardial infarction (PI), cardiac arrest and cerebrovascular events) at 6 months.</measure>
    <time_frame>6-months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">2500</enrollment>
  <condition>Trauma</condition>
  <condition>Traumatic Injury</condition>
  <condition>Traumatic Brain Injury</condition>
  <condition>Wounds and Injuries</condition>
  <condition>Penetrating Injury</condition>
  <condition>Blunt Injury</condition>
  <condition>Major Trauma</condition>
  <condition>Multiple Trauma</condition>
  <arm_group>
    <arm_group_label>Erythropoietin (EPO)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Epoetin alfa 40,000 IU (1mL pre-filled syringe) will be given by subcutaneous injection to eligible patients on Study Days 1 and 8 during the intensive care unit stay.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Sodium Chloride 0.9% (1mL in volume) will be given by subcutaneous injection to eligible patients allocated to the placebo arm on Study Days 1 and 8 during the intensive care unit stay.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epoetin Alfa 40000 UNT/ML</intervention_name>
    <description>Epoetin alfa 40,000IU 1mL pre-filled syringe given as subcutaneous injection.</description>
    <arm_group_label>Erythropoietin (EPO)</arm_group_label>
    <other_name>Eprex</other_name>
    <other_name>Binocrit</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium Chloride 0.9%</intervention_name>
    <description>Sodium Chloride 0.9% 1mL in volume given as subcutaneous injection.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo</other_name>
    <other_name>Saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: Patients with trauma admitted to the ICU who:&#xD;
&#xD;
          -  Are ≥ 18 to ≤ 75 years of age&#xD;
&#xD;
          -  Are &lt; 24 hours since primary traumatic injury&#xD;
&#xD;
          -  Are invasively mechanically ventilated&#xD;
&#xD;
          -  Are expected to stay in the ICU ≥ 48 hours&#xD;
&#xD;
          -  Have a haemoglobin not exceeding the upper limit of the applicable normal (ULN)&#xD;
             reference range in clinical use at the treating institution&#xD;
&#xD;
          -  Have informed consent from a legal surrogate according to local law&#xD;
&#xD;
        Exclusion Criteria: Patients will be excluded from the study if any of the following&#xD;
        criteria apply:&#xD;
&#xD;
          -  GCS = 3 and fixed dilated pupils&#xD;
&#xD;
          -  Recent history of DVT, PE or other thromboembolic event (within previous 12 months or&#xD;
             receiving concomitant anticoagulant treatment for this indication)&#xD;
&#xD;
          -  A chronic hypercoagulable disorder, including known malignancy&#xD;
&#xD;
          -  Treatment with EPO in the last 30 days&#xD;
&#xD;
          -  First dose of study drug unable to be given within 24 hours of primary injury&#xD;
&#xD;
          -  Pregnancy or lactation or 3 months postpartum&#xD;
&#xD;
          -  Expected to die imminently (&lt; 24 hours)&#xD;
&#xD;
          -  Known sensitivity to mammalian cell derived products&#xD;
&#xD;
          -  Known contraindication to epoetin alfa&#xD;
&#xD;
          -  End stage renal failure (receives chronic dialysis)&#xD;
&#xD;
          -  Severe pre-existing physical or mental disability or severe co-morbidity that may&#xD;
             interfere with the assessment of outcome&#xD;
&#xD;
          -  The treating physician believes it is not in the best interest of the patient to be&#xD;
             randomised to this trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>A/Professor Craig French</last_name>
    <role>Study Chair</role>
    <affiliation>Western Health; ANZIC Research Centre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Professor Alistair Nichol</last_name>
    <role>Study Chair</role>
    <affiliation>University College Dublin; ANZIC Research Centre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vicki Papanikolaou</last_name>
    <phone>+61 409 142 695</phone>
    <email>vicki.papanikolaou@monash.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Royal Prince Alfred Hospital</name>
      <address>
        <city>Camperdown</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>David Gattas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St Vincent's Hospital Sydney</name>
      <address>
        <city>Darlinghurst</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>David Lowe</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St George Hospital</name>
      <address>
        <city>Kogarah</city>
        <state>New South Wales</state>
        <zip>2217</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Kush Deshpande</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>John Hunter Hospital</name>
      <address>
        <city>New Lambton Heights</city>
        <state>New South Wales</state>
        <zip>2305</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Zsolt Balogh</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal North Shore Hospital</name>
      <address>
        <city>Saint Leonards</city>
        <state>New South Wales</state>
        <zip>2065</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Chris Andersen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Westmead Hospital</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Vineet Nayyar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cairns Hospital</name>
      <address>
        <city>Cairns</city>
        <state>Queensland</state>
        <zip>4870</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Catherine Tacon</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Brisbane and Women's Hospital</name>
      <address>
        <city>Herston</city>
        <state>Queensland</state>
        <zip>4029</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Michael Reade</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gold Coast University Hospital</name>
      <address>
        <city>Southport</city>
        <state>Queensland</state>
        <zip>4215</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Don Campbell</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Princess Alexandra Hospital</name>
      <address>
        <city>Woolloongabba</city>
        <state>Queensland</state>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Adam Suliman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Hobart Hospital</name>
      <address>
        <city>Hobart</city>
        <state>Tasmania</state>
        <zip>7000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>David Cooper</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Alfred Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Dashiell Gantner</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Melbourne Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Yasmine Ali Abdelhamid</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Perth Hospital</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>6000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Robert McNamara</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St Vincent's University Hospital</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Auckland City Hospital</name>
      <address>
        <city>Grafton</city>
        <state>Auckland</state>
        <zip>1023</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Colin McArthur</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Middlemore Hospital</name>
      <address>
        <city>Auckland</city>
        <state>Otahuhu</state>
        <zip>1640</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Tony Williams</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Waikato Hospital</name>
      <address>
        <city>Hamilton</city>
        <state>Waikato</state>
        <zip>3204</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Robert Martynoga</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wellington Hospital</name>
      <address>
        <city>Newtown</city>
        <state>Wellington</state>
        <zip>6021</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>James Moore</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Christchurch Hospital</name>
      <address>
        <city>Christchurch</city>
        <zip>8011</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Brandon Burke</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Ireland</country>
    <country>New Zealand</country>
  </location_countries>
  <results_reference>
    <citation>Nichol A, French C, Little L, Haddad S, Presneill J, Arabi Y, Bailey M, Cooper DJ, Duranteau J, Huet O, Mak A, McArthur C, Pettilä V, Skrifvars M, Vallance S, Varma D, Wills J, Bellomo R; EPO-TBI Investigators; ANZICS Clinical Trials Group. Erythropoietin in traumatic brain injury (EPO-TBI): a double-blind randomised controlled trial. Lancet. 2015 Dec 19;386(10012):2499-506. doi: 10.1016/S0140-6736(15)00386-4. Epub 2015 Oct 6.</citation>
    <PMID>26452709</PMID>
  </results_reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>October 1, 2020</study_first_submitted>
  <study_first_submitted_qc>October 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2020</study_first_posted>
  <last_update_submitted>August 24, 2021</last_update_submitted>
  <last_update_submitted_qc>August 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Intensive Care Unit</keyword>
  <keyword>Trauma</keyword>
  <keyword>Major trauma</keyword>
  <keyword>Traumatic injury</keyword>
  <keyword>EPO</keyword>
  <keyword>Erythropoietin</keyword>
  <keyword>Epoetin alfa</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Injuries</mesh_term>
    <mesh_term>Brain Injuries, Traumatic</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
    <mesh_term>Multiple Trauma</mesh_term>
    <mesh_term>Wounds, Nonpenetrating</mesh_term>
    <mesh_term>Wounds, Penetrating</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epoetin Alfa</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>At the conclusion of the study, the study management committee will consider requests from researchers who provide a methodically sound scientific proposal as per the Data Sharing Policy set out in the ANZIC-RC Terms of Reference.</ipd_description>
    <ipd_time_frame>As per the ANZIC Research Centre Data Sharing Policy</ipd_time_frame>
    <ipd_access_criteria>As per the ANZIC Research Centre Data Sharing Policy</ipd_access_criteria>
    <ipd_url>https://www.monash.edu/__data/assets/pdf_file/0010/2153899/2020-03-19-ANZIC-RC-Terms-of-Reference.pdf</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

